Who funds Alzheimer's disease drug development?

Cummings, Jeffrey L.; Bauzon, Justin; Lee, Garam

doi:10.1002/trc2.12185

Cited by 8 publications

(8 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The economic impact is huge; in fact, AD represents a public health financial burden of ~1 trillion US dollars annually. Due to the rapid ageing of the population, it is expected that these numbers will double over the next two decades [ 1 , 2 ]. Unfortunately, none of the currently available treatments has shown clinical efficacy in delaying the onset and/or curing already established AD.…”

Section: Introductionmentioning

confidence: 99%

Epilepsy and Alzheimer’s Disease: Current Concepts and Treatment Perspective on Two Closely Related Pathologies

Leo

Tallarico

Sciaccaluga

et al. 2022

View full text Add to dashboard Cite

The literature of epileptic seizures in Alzheimer's disease has significantly increased over the past decades. Remarkably, several studies suggest a bi-directional link between these two common neurological diseases, with either condition carrying a nearly 2-fold risk of contracting the other in comparison to healthy subjects. In this respect, evidence from both clinical and preclinical studies indicate that epileptogenesis and neurodegeneration possibly share common underlying mechanisms. However, the precise association between epileptogenesis and neurodegeneration still needs to be fully elucidated. Targeted intervention to reduce abnormal network hyperexcitability might constitute a therapeutic strategy to postpone the onset of later neurodegenerative changes and consequent cognitive decline by many years in patients. By virtue of this, an early diagnosis and treatment of seizures in patients with Alzheimer’s diseases should be pursued. To date, no guidelines are available for treating epileptic activity in this context, largely due to the paucity of studies sufficient to answer this question. Accordingly, clinical trials are mandatory, not only to inform clinicians about symptomatic management of seizures, in Alzheimer’s disease patients, but also to detect if a treatment with antiseizure medications could have disease-modifying effects. Moreover, it will be fundamental to expand the application of animal models of Alzheimer’s disease to comorbid conditions such as epilepsy both to reveal the mechanisms underlying seizure onset and to better define their role in cognitive decline. Such models could be also useful to identify pharmacological compounds therapeutically effective as well as reliable early biomarkers for seizures in Alzheimer’s Disease.

show abstract

Section: Introductionmentioning

confidence: 99%

Epilepsy and Alzheimer’s Disease: Current Concepts and Treatment Perspective on Two Closely Related Pathologies

Leo

Tallarico

Sciaccaluga

et al. 2022

View full text Add to dashboard Cite

show abstract

“…and the tremendous amount of participant time devoted to trials of-concept and are more likely to be funded by NIH (56%) than biopharmaceutical sponsors (21%). 42 Global participation in drug development is evident in this review. Sixty-three percent of Phase 3 trials and 46%…”

Section: Discussionmentioning

confidence: 94%

“…The NIH and academic medical centers play a large role in Phase 2 proof‐of‐concept studies (36% of trials) and a smaller role in late‐stage drug development (15% of Phase 3 trials). Repurposed agents have a greater role in proof‐of‐concept and are more likely to be funded by NIH (56%) than biopharmaceutical sponsors (21%) 42 . Global participation in drug development is evident in this review.…”

Section: Discussionmentioning

confidence: 97%

Alzheimer's disease drug development pipeline: 2022

Cummings

Lee

Nahed

et al. 2022

A&D Transl Res & Clin Interv

Self Cite

379

256

View full text Add to dashboard Cite

Introduction: Alzheimer's disease (AD) represents a global health crisis. Treatments are needed to prevent, delay the onset, slow the progression, improve cognition, and reduce behavioral disturbances of AD. We review the current clinical trials and drugs in development for the treatment of AD. Methods: We searched the governmental website clinicaltrials.gov where are all clinical trials conducted in the United States must be registered. We used artificial intelligence (AI) and machine learning (ML) approaches to ensure comprehensive detection and characterization of trials and drugs in development. We use the Common Alzheimer's Disease Research Ontology (CADRO) to classify drug targets and mechanisms of action of drugs in the pipeline. Results: As of January 25, 2022 (index date for this study) there were 143 agents in 172 clinical trials for AD. The pipeline included 31 agents in 47 trials in Phase 3, 82 agents in 94 trials in Phase 2, and 30 agents in 31 trials in Phase 1. Disease-modifying therapies represent 83.2% of the total number of agents in trials; symptomatic cognitive enhancing treatments represent 9.8% of agents in trials; and drugs for the treatment of neuropsychiatric symptoms comprise 6.9%. There is a diverse array of drug targets represented by agents in trials including nearly all CADRO categories. Thirtyseven percent of the candidate agents in the pipeline are repurposed drugs approved for other indications. A total of 50,575 participants are needed to fulfill recruitment requirements for all currently active clinical trials. Discussion: The AD drug development pipeline has agents representing a substantial array of treatment mechanisms and targets. Advances in drug design, outcome measures, use of biomarkers, and trial conduct promise to accelerate the delivery of new and better treatments for patients with AD.

show abstract

“…This is largely because drugs are often developed initially for AD or PD and later directed towards DLB. We found that most DLB clinical trials, and in particular the repurposing of agents, were sponsored by academic centers, likely related to complexities around IP within the biopharma industry [12,26].…”

Section: Discussionmentioning

confidence: 98%

Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022

et al. 2023

View full text Add to dashboard Cite

Introduction: Reviews of randomized clinical trials (RCTs) in dementia with Lewy bodies (DLB) are essential for informing ongoing research efforts of symptomatic therapies and potentially disease-modifying therapies (DMTs).Methods: We performed a systematic review of all clinical trials conducted until September 27, 2022, by examining 3 international registries: ClinicalTrials.gov, the European Union Drug Regulating Authorities Clinical Trials Database, and the International Clinical Trials Registry Platform, to identify drugs in trials in DLB. Results: We found 25 agents in 40 trials assessing symptomatic treatments and DMTs for DLB: 7 phase 3, 31 phase 2, and 2 phase 1 trials. We found an active pipeline for drug development in DLB, with most ongoing clinical trials in phase 2. We identified a recent trend

show abstract

Who funds Alzheimer's disease drug development?

Cited by 8 publications

References 36 publications

Epilepsy and Alzheimer’s Disease: Current Concepts and Treatment Perspective on Two Closely Related Pathologies

Epilepsy and Alzheimer’s Disease: Current Concepts and Treatment Perspective on Two Closely Related Pathologies

Alzheimer's disease drug development pipeline: 2022

Dementia with Lewy Bodies Drug Therapies in Clinical Trials: Systematic Review up to 2022

Contact Info

Product

Resources

About